Vice President Mike Pence on November 19, 2020, James S. of the White House. Brady spoke to US Health and Human Services Secretary Alex Azar during a White House Coronavirus task force press conference in the briefing room.
Brendan Smilowski | AFP | Getty Images
Health and Human Services Secretary Alex Azar said on Thursday that Pfizer is expected to file an application to the FDA on Friday for emergency use of its coronavirus vaccine, which Modern will soon follow to comply.
Azar said during the first public meeting of the White House Coronavirus Task Force, “Pfizer’s partner, BioNotech, has announced that they intend to file for the Emergency Use Authority at the FDA tomorrow.” “We will hopefully have a modern filing soon.
On Wednesday, Pfizer said the FDA was expected to submit an application “within the last days” after a final data analysis found that its coronavirus vaccine was highly effective and appeared safe. Three days after the initial phase of modernity The news came two days later, according to data from the study. The vaccine was 94.5%. Both vaccines use messenger RNA, or mRNA, technology. This is a new approach to vaccines that uses genetic material to provoke an immune response. Does.
In almost every country, a safe and effective vaccine is seen by investors and policy makers as a way to get the global economy back on track after the pandemic. According to data compiled by Johns Hopkins University, coronavirus is spreading rapidly across the United States, infecting more than 11.53 million Americans and killing at least 250,548 people.
At the same meeting, Vice President Mike Pence stated that the US “could be away in a few weeks before the vaccine becomes available to the most vulnerable.” While it is true that some Americans may receive their first dose of vaccine in about a month, this vaccine will initially be very limited.
Azar told CNBC on Monday that about 40 million vaccines are available between the two companies by the end of this year, vaccinating about 20 million people. The US has also signed supply agreements for Kovid-19 vaccines from Johnson & Johnson; Sanofi and GlaxoSmithKline; Novavax and AstraZeneca.